Management of potential neurocysticercosis in patients with HIV infection.
In patients with human immunodeficiency virus, the diagnosis of neurocysticercosis can be complex, and the current diagnostic criteria may not apply. We report 3 cases and suggest including the CD4+ T lymphocyte count as an important factor in the proper diagnosis and treatment of patients with human immunodeficiency virus and potential neurocysticercosis.
Prasad
Sashank
S
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA. Sashank.prasad@uphs.upenn.edu
MacGregor
Rob Roy
RR
Tebas
Pablo
P
Rodriguez
Lourdes B
LB
Bustos
Javier A
JA
White
A Clinton
AC
D000328:Adult; D000368:Aged; D000871:Anthelmintics / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications / Q000276:immunology*; D006801:Humans; D007118:Immunoassay; D016867:Immunocompromised Host; D018655:Lymphocyte Count; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020019:Neurocysticercosis / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D012008:Recurrence
D000871:Anthelmintics; D044966:Anti-Retroviral Agents; D005938:Glucocorticoids